SEC Comment Letter for GALECTIN THERAPEUTICS INC (GALT) (CIK 0001133416) (GALT) — May 30, 2017
GALECTIN THERAPEUTICS INC (GALT) (CIK 0001133416)
Date: May 30, 2017 · CIK: 0001133416 · Accession: 0000000000-17-018858
AI Filing Summary & Sentiment
Reasoning
Letter
May 30, 2017 Peter G. Traber Chief Executive Officer and President Galectin Therapeutics Inc. 4960 Peachtree Industrial Blvd, Suite 240 Norcross, Georgia 30071 Galectin Therapeutics Inc. Registration Statement on Form S-3 Filed May 19, 2017 File No. 333-218112Re: Dear Dr. Traber: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jeffrey Gabor at (202) 551-2544 with any questions. Division of Corporation Finance Office of Healthcare and Insurance
Show Raw Text
May 30, 2017
Peter G. Traber
Chief Executive Officer and President
Galectin Therapeutics Inc.
4960 Peachtree Industrial Blvd, Suite 240
Norcross, Georgia 30071
Galectin Therapeutics Inc.
Registration Statement on Form S-3
Filed May 19, 2017
File No. 333-218112Re:
Dear Dr. Traber:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jeffrey Gabor at (202) 551-2544 with any questions.
Division of Corporation Finance
Office of Healthcare and
Insurance